Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tralesinidase alfa in MPS IIIB
NCT02754076Phase 2Completed
- Sponsor
- Allievex
- Start
- Apr 2016
- Primary completion
- Jun 2020
- Modality
- Replacement Enzymes, Fc-Fusion Proteins
- Countries
- 7
01
Overview
Phase 2, open-label, single-arm trial of tralesinidase alfa in mucopolysaccharidosis type IIIB, sponsored by Allievex. Primary endpoints: Safety Evaluation of weekly infusions of AX 250 up to 124 weeks and Development Quotient up to 124 weeks. Started Apr 2016; status: completed.
02
Drugs
tralesinidase alfa
03
Conditions
mucopolysaccharidosis type IIIB
Beyond the preview
Go deeper on NCT02754076.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02754076.